Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
Abstract The endocannabinoid system (ECS), a signalling network with immunomodulatory properties, is a potential therapeutic target in multiple sclerosis (MS). Dimethyl fumarate (DMF) is an approved drug for MS whose mechanism of action has not been fully elucidated; the possibility exists that its...
Main Authors: | Alicia Sánchez-Sanz, María Posada-Ayala, Julia Sabín-Muñoz, Ismael Fernández-Miranda, Yolanda Aladro-Benito, Roberto Álvarez-Lafuente, Ana Royuela, Ruth García-Hernández, Ofir Rodríguez-De la Fuente, Julián Romero, Antonio García-Merino, Antonio José Sánchez-López |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21807-y |
Similar Items
-
Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients
by: Alicia Sánchez-Sanz, et al.
Published: (2023-07-01) -
Drug-Repurposing Strategy for Dimethyl Fumarate
by: Salvatore Giunta, et al.
Published: (2023-07-01) -
Dimethyl fumarate transfer into human milk
by: Andrea I. Ciplea, et al.
Published: (2020-10-01) -
Effects of dimethyl fumarate on neuroprotection and immunomodulation
by: Albrecht Philipp, et al.
Published: (2012-07-01) -
A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01)